Following an inter partes review requested by 10x Genomics, the Patent Trial and Appeal Board invalidated a number of claims in a RainDance patent.
Terms of the deal have not been disclosed, but the firms expect to finalize the acquisition in the first quarter of 2017.
The company has scaled back its headcount from a peak of 115 employees to about 100 staff members, primarily on the commercial side.
The UCSF-based Blood Systems Research Institute will conduct research using RainDance's digital PCR platforms as part of a new $20 million amfAR Institute for HIV Cure Research.
The work identified specific groups of somatic mutations that might be ideal to hunt for in ctDNA to monitor tumor burden, guide treatment, or follow therapeutic response.
The company filed to go public in March with plans to offer up to $60 million of its stock.
The company has established a streamlined workflow that customizes and automates key steps of the sample prep process.
The solutions will combine RainDance's digital droplet technology and single-molecule barcoding technology with PacBio's proprietary long-range DNA amplification technology.
The agreements are to distribute RainDance's products in Central and Eastern Europe, Italy, Switzerland, Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.
The firm said that it plans to list its stock on the Nasdaq under ticker symbol "RAIN" and added that its 2014 revenues were up 78 percent year over year to $30.6 million.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.